SCHEMBL2272852

SCHEMBL2272852

O=C(Nc1cc(-c2ccc3c(c2)OCO3)ccc1C(=O)O)c1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
HPGD P15428 3/20 0.55
ALDH1A1 P00352 3/20 0.55
RAB9A P51151 10/20 0.52
NPC1 O15118 10/20 0.52
PKM P14618 2/20 0.52
PTGS2 P35354 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
KDM4E B2RXH2 1/20 0.50
KMT2A Q03164 5/20 0.49
MEN1 O00255 3/20 0.49
POLB P06746 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
GAA P10253 1/20 0.48
MAOB P27338 1/20 0.48
GRIK1 P39086 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272541 0.90 PTGS2 (0.63) CASP3SENP8SENP7SENP6HPGD
SCHEMBL2274795 0.89 NPC1 (0.60) HPGDALDH1A1RAB9ANPC1PKM
SCHEMBL2272940 0.89 NPC1 (0.62) HPGDALDH1A1RAB9ANPC1PKM
SCHEMBL2276661 0.85 RAB9A (0.58) CASP3SENP8SENP7SENP6HPGD
SCHEMBL2273182 0.85 PTGS2 (0.66) CASP3SENP8SENP7SENP6HPGD
SCHEMBL2276199 0.84 ALDH1A1 (0.51) CASP3SENP8SENP7SENP6HPGD
SCHEMBL2277756 0.84 PTGS2 (0.57) CASP3SENP7HPGDALDH1A1RAB9A
SCHEMBL4218151 0.83 KMT2A (0.52) CASP3SENP8SENP7SENP6ALDH1A1
SCHEMBL28771368 0.82 ALDH1A1 (0.49) CASP3SENP8SENP7SENP6HPGD
SCHEMBL2271243 0.82 ADCY1 (0.61) HPGDALDH1A1RAB9ANPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 CASP3 139/4885SENP8 2469/4885SENP7 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.